{"entity":{"id":"nct07823049","kind":"trial","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","aka":[],"tldr":"A phase 3 trial of XNW28012 for injection in pancreatic ductal adenocarcinoma, run by Evopoint Biosciences Inc., now recruiting.","summary":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy is a phase 3 interventional study registered as NCT07823049 by Evopoint Biosciences Inc., with 226 participants planned, started 2025-07-08 and due to reach its primary completion in 2027-05-31. Interventions recorded: XNW28012 for injection and XNW28012 Mimetic for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07823049","url":"https://clinicaltrials.gov/study/NCT07823049"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["evopoint-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07823049","phase":"3","setting":"A Randomized, Double-blind, Multicenter Phase III Clinical Study Comparing XNW28012 Versus Placebo in Combination With Best Supportive Care in Patients With Metastatic Pancreatic Cancer Who Have Received Prior Systemic Therapy","sponsor":"Evopoint Biosciences Inc.","enrolled":226,"outcomes":[]},"route":"/trials/nct07823049/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"}]}}